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Diabetes mellitus is a chronic metabol-
ic disease, which is characterised by in-
creased blood sugar concentrations as a 
result of an absolute or relative lack of in-
sulin. An absolute lack of insulin charac-
terises “type-1 diabetes”, which manifests 
itself mainly during childhood or adoles-
cence. It is caused by an autoimmune de-
struction of the insulin-producing beta 
cells of the pancreas [1]. A relative lack 
of insulin characterises “type-2 diabetes”, 
which primarily occurs in adulthood. 
Here, the impaired glucose metabolism 
results from a reduced insulin effect in 
conjunction with inadequately compen-
sating insulin secretion. In addition to 
genetic predisposition, the main risk fac-
tors include a diet related to the “West-
ern” lifestyle, lack of exercise and associ-
ated excess weight [1, 2]. A relative lack of 
insulin can also develop for the first time 
during pregnancy, which generally sub-
sequently disappears (“gestational diabe-
tes”). However, a high risk remains of de-
veloping a manifest type-2 diabetes in lat-
er life [1].
Long-term increased blood sugar con-
centrations in the case of as-yet undiag-
nosed diabetes or an inadequately con-
trolled diagnosed diabetes leads to dam-
age of the blood vessels and peripheral 
nerves. This results in an increased risk of 
cardiovascular diseases such as heart at-
tack and stroke, as well as of kidney fail-
ure, blindness and foot amputations [1, 3]. 
These health complications, in addition to 
the diabetes itself, lead to a lesser quality 
of life and reduced life expectancy of those 
affected [3, 4], as well as to high costs for 
the health care system [5].
International analyses show that the 
number of adults with diabetes world-
wide has more than doubled in the last 
three decades [6]. This trend mainly re-
flects the increase in type-2 diabetes [2]. 
It is assumed that the disease has not yet 
been diagnosed in approximately half of 
those affected [7].
German studies on prevalence esti-
mates of known diabetes are based most-
ly on data from regional studies, health 
insurance companies or general practices 
assessed at least 5–10 years ago (see sum-
mary in . Tab. 6). Nationwide, popula-
tion-based data on known diabetes were 
provided most recently via the telephone 
surveys “German Health Update” (GE-
DA) 2009 [8, 9] and GEDA 2010 [10]. 
There are only isolated studies on undiag-
nosed diabetes [11].
On the basis of data from the Health 
Interview and Examination Survey con-
ducted from 2008 to 2011, the following 
article presents up-to-date, representative 
estimates regarding lifetime prevalence of 
known diabetes in the resident population 
of Germany aged 18–79 years. The tempo-
ral trend is shown in comparison with the 
last Health Interview and Examination 
Survey from 1997 to 1999. The results are 
presented and discussed in the context of 
previous studies in Germany. For the pur-
pose of assessing the prevalence and tem-
poral trend of undiagnosed diabetes, labo-
ratory data that are comparable over time 
are required. This is currently being cross-
calibrated for both surveys and is there-
fore not included as part of the paper.
Methods
Study design
The “German Health Interview and Ex-
amination Survey for Adults” (DEGS) 
is part of the health monitoring sys-
tem at the Robert Koch Institute (RKI). 
The concept and design of DEGS are de-
scribed in detail elsewhere [12, 13, 14, 15, 
16]. The first wave of the survey (DEGS1) 
was conducted from 2008 to 2011 and 
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comprised interviews, examinations and 
tests [17, 18]. The target population com-
prises the residents of Germany aged 
18–79 years. DEGS1 has a mixed design, 
which allows for both cross-sectional 
and longitudinal analyses. For this pur-
pose, a random sample from local pop-
ulation registries was drawn to complete 
the sample of participants of the “Ger-
man National Health Interview and Ex-
amination Survey 1998” (GNHIES98) 
who re-participated. A total of 8,152 per-
sons participated, including 4,193 first-
time invitees (response rate: 42%) and 
3,959 revisiting participants of the GN-
HIES98 (response rate: 62%). In all, 
7,238 persons visited one of the 180 ex-
amination centres, and 914 were inter-
viewed only. The net sample allows for 
representative cross-sectional and trend 
analyses for the age range of 18–79 years 
(n=7,988, including 7,116 in examination 
centres) in comparison with GNHIES98 
((n=7,124) [16]. The data of the revisit-
ing participants are suitable for longitu-
dinal analyses.
The cross-sectional analyses on 
known diabetes are based on the da-
ta of 7,116 participants aged 18–79 years 
who completed the examination part of 
DEGS1. In an additional analysis, the 
diabetes prevalence established in this 
sample was compared with that in the 
total net sample (n=7,988), which also 
contained data from those surveyed by 
interview only. The participants of GN-
HIES98 (n=7,124) were included in the 
temporal comparison. Participants with 
missing data regarding diabetes diagno-
sis were excluded from the analyses, pro-
vided they were not taking anti-diabetics 
(DEGS1: n=36; GNHIES98: n=25).
Definition of known diabetes
Lifetime prevalence of known diabetes 
was established using the following case 
definition:
F  Answering yes to the question “Have 
you ever been diagnosed with dia-
betes by a doctor?” as part of a stan-
dardised, computer-aided and physi-
cian-administered interview or
F  Taking of anti-diabetics having been 
documented as part of an automated 
assessment of medication taken with-
in the past 7 days.
The physician-administered interview 
did not include any direct questions on 
the type of diabetes. However, the pro-
portion of type-1 diabetes was estimated 
by gathering the following additional in-
formation:
F  Age at diagnosis <30 years, and
F  Insulin treatment immediately after 
diagnosis, and
F  Current insulin treatment.
In addition, women with a diagnosis of 
diabetes before the age of 50 years were 
asked in the DEGS1 whether they were 
pregnant at the time of diagnosis. The 
proportion of gestational diabetes was es-
timated by linking with additional infor-
mation as follows:
F  Diagnosis during pregnancy, and
F  Not currently taking anti-diabetics, 
and
F  No existing diabetes in the past 
12 months (n=32) or in the case of 
missing data (n=6) or in the case of 
unclear answer (n=4) with regard 
to diabetes existing within the past 
12 months: HbA1c <6.5% and glucose 
<7.0 mmol/l (fasting)/<11.1 mmol/l 
(non-fasting).
One participant that stated“diagnosis dur-
ing pregnancy” was pregnant when inter-
viewed. Because of additional informa-
tion (diagnosis 3 years ago, diabetes exist-
ing in the past 12 months, current treat-
ment with insulin and treatment immedi-
ately after diagnosis by tablet), type-2 dia-
betes rather than gestational diabetes was 
assumed in this case.
Statistical analysis
The cross-sectional and trend analyses 
were conducted using a weighting factor, 
which corrects sample deviations from the 
population structure (as of 31 December 
2010) with regard to age, sex, region and 
nationality, as well as type of communi-
ty and education [16]. A separate weight-
ing factor was created for the examina-
tion part. Calculation of the weighting 
factor also considered the re-participa-
tion probability of the GNHIES98 partic-
ipants based on a logistic regression mod-
el. For the purpose of conducting trend 
analyses, the data from GNHIES98 were 
age-adjusted to the population structure 
as of 31 December 2010. A non-response 
analysis and a comparison of selected in-
dicators with data from census statistics 
indicated a high level of sample repre-
sentativeness for the resident population 
of Germany aged 18–79 years [16]. In or-
der to take into account both the weight-
ing and the correlation of the participants 
within a community, the confidence inter-
vals and p values were determined using 
the survey procedures for complex sam-
ples in SAS 9.2. Differences with p values 
of <0.05 were considered to be statistical-
ly significant.
Estimates of the lifetime prevalence of 
diabetes in cross-sectional and trend anal-
yses are presented for the population aged 
18–79 years in general, as well as stratified 
by gender. Additional stratification vari-
ables in the cross-sectional analyses are 
age, socioeconomic status, residential re-
gion and health insurance company. So-
cioeconomic status was determined us-
ing an index that includes information re-
garding school education and vocation-
al training, professional status and net 
household income (weighted by house-
hold needs) and which allows classifica-
tion into either the low, middle or high 
Tab. 1 Lifetime prevalence (percent, 95% confidence interval) of known diabetes according 
to gender and age groups. Nunweighted=7,080
Age group in 
years
18–39 40–49 50–59 60–69 70–79 Overall
Gender            






































status group [19]. The residential region 
was stratified into new federal states (in-
cluding Berlin) and old federal states for 
the purpose of comparisons with previous 
surveys. For further regional differentia-
tion, the old federal states were sub-divid-
ed into North (Schleswig-Holstein, Ham-
burg, Lower Saxony, Bremen), Central 
(North Rhine-Westphalia, Hesse, Rhine-
land Palatinate, Saarland) and South (Ba-
varia, Baden-Wuerttemberg). Health in-
surance companies were categorised into 
statutory health insurance, private health 
insurance as comprehensive health insur-
ers and other health care provision (bene-
fit aid, foreign health insurance, other en-
titlement, no health insurance/self-payer). 
In addition and analogous to earlier tele-
phone surveys, the statutory health insur-
ance providers were sub-divided into lo-
cal health insurance funds (AOK), sub-
stitute health insurance funds, company 
health insurance funds and other statu-
tory health insurance funds. By compar-
ing non-adjusted and age-adjusted logis-
tical regression models, the influence of 
age on the relationship between the re-
spective stratification variable and preva-
lence of diabetes was evaluated.
Results
Prevalence of known diabetes
In total, 591 of the 7,080 participants of the 
DEGS1 examination part stated they had 
been diagnosed with diabetes by a doctor 
at some point. . Tab. 1 shows the corre-
sponding lifetime prevalence of known 
diabetes for the population aged 18–
79 years of 7.2% overall (women: 7.4%; 
men: 7.0%). For both sexes the prevalence 
increases substantially with age from un-
der 5% amongst those under 50 years of 
age to around 22% in the 70- to 79-year-
olds.
An analysis of the total net sample, 
which also included participants surveyed 
by means of interview only, yielded com-
parable results with 677 of the 7,934 par-
ticipants included having a diabetes diag-
nosis or a lifetime prevalence overall of 
7.4% (women: 7.5%; men: 7.2%).
The prevalence of type-1 diabetes was 
ascertained as being around 0.1% (n=8). 
This corresponds to a proportion of 
1.1% of the total prevalence of known di-
abetes. The prevalence of gestational dia-
betes amongst women amounted to 1.2% 
(n=42). This corresponds to a proportion 
of 16.3% of the total prevalence of known 
diabetes amongst women.
. Tab. 2 reflects a significantly high-
er lifetime prevalence of known diabe-
tes for women and men of low socioeco-
nomic status than for those of high socio-
economic status. This difference is more 
strongly pronounced in women than in 
men. While women of middle socio-
economic status also show a significant-
ly higher prevalence than those of high 
socioeconomic status, there is no differ-
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Abstract
The first wave of the “German Health Inter-
view and Examination Survey for Adults” 
(DEGS1, 2008–2011) allows for up-to-date, 
representative prevalence estimates of 
known diabetes amongst the 18- to 79-year-
old resident population of Germany. Tempo-
ral trends can be shown by comparing the 
survey findings with those of the “German 
National Health Interview and Examination 
Survey 1998” (GNHIES98). The definition of 
known diabetes was based on self-reports in 
physician-administered interviews that asked 
respondents if they had ever been diagnosed 
with diabetes by a doctor or were on anti-dia-
betic medication. Overall, diabetes had been 
diagnosed in 7.2% of the adults (7.4% of the 
women; 7.0% of the men). The prevalence in-
creased substantially with advancing age and 
was higher in persons of low than of high so-
cioeconomic status. Prevalence varied de-
pending on the type of health insurance held 
and was highest amongst those insured with 
AOK health insurance funds. In comparison 
with GNHIES98, there was a 38% increase in 
prevalence, of which approximately one third 
is to be attributed to demographic ageing. In 
the context of other nationwide studies, the 
results indicate a figure of at least 4.6 million 
18- to 79-year-olds having been diagnosed 
with diabetes at some point. Planned analy-
ses of undiagnosed diabetes will contribute 
to the interpretation of the observed increase 
in the prevalence of known diabetes.
Keywords
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Prävalenz und zeitliche Entwicklung des bekannten 
Diabetes mellitus. Ergebnisse der Studie zur 
Gesundheit Erwachsener in Deutschland (DEGS1)
Zusammenfassung
Die erste Welle der „Studie zur Gesundheit 
 Erwachsener in Deutschland“ (DEGS1, 2008–
2011) ermöglicht aktuelle, repräsentative 
Prävalenzschätzungen des bekannten Di-
abetes in der 18- bis 79-jährigen Wohnbe-
völkerung. Im Vergleich zum „Bundes-Ge-
sundheitssurvey 1998“ (BGS98) lässt sich die 
zeitliche Entwicklung darstellen. Die Defi-
nition des bekannten Diabetes beruht auf 
Selbstangaben zu einem jemals ärztlich fest-
gestellten Diabetes in ärztlichen Interviews 
oder der Einnahme von Antidiabetika. Ins-
gesamt wurde bei 7,2% der Erwachsenen 
(7,4% der Frauen; 7,0% der Männer) jemals 
ein Diabetes diagnostiziert. Die Prävalenz 
steigt mit zunehmendem Alter deutlich an 
und ist bei niedrigem Sozialstatus höher als 
bei hohem Sozialstatus. Die Prävalenz vari-
iert je nach Krankenversicherungsart und ist 
für Versicherte der Allgemeinen Ortskran-
kenkasse (AOK) am höchsten. Im Vergleich 
zum BGS98 zeigt sich ein Prävalenzanstieg 
um 38%, wovon etwa ein Drittel auf die de-
mografische Alterung zurückzuführen ist. 
Die Ergebnisse weisen im Kontext mit an-
deren bundesweiten Studien auf aktuell min-
destens 4,6 Mio. 18- bis 79-Jährige mit einer 
Diabetesdiagnose hin. Geplante Analysen 
zum nicht diagnostizierten Diabetes werden 
zur Interpretation des beobachteten Präva-
lenzanstiegs des bekannten Diabetes bei-
tragen.
Schlüsselwörter
Diabetes mellitus · Deutschland ·  
Erwachsene · Gesundheitssurvey · Prävalenz
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ence in prevalence between men of mid-
dle and high socioeconomic status. These 
results were also observed in the age-ad-
justed model.
In the stratification of the lifetime 
prevalence of known diabetes according 
to residential area, as shown in . Tab. 3, 
there tends to be a higher prevalence for 
the new federal states than for the old fed-
eral states, which is more pronounced 
amongst women than men. Further strat-
ification of the old federal states into 
North, Central and South indicates that 
there tends to be a higher prevalence in 
the Central region compared to the North 
or South. These observed trends, howev-
er, are not statistically significant. They 
remain in the age-adjusted model but are 
even less pronounced.
. Tab. 4 shows differences in the life-
time prevalence of known diabetes de-
pending on the type of health insurance. 
Statutory health insurees have a higher 
prevalence overall (7.5%) than those pri-
vately insured (3.8%). Amongst persons 
insured in statutory schemes, those cov-
ered through AOK have the highest prev-
alence at 9.0%, whereas those covered 
through company health insurance funds 
have the lowest prevalence at 5.9%. This 
pattern is also evident in the gender-strat-
ified analysis, although the prevalence 
difference is less pronounced between the 
various statutory health insurance funds 
amongst women and between the statu-
tory and the private funds amongst men. 
This pattern is also observed in the age-
adjusted model, although the differences 
are less pronounced.
Trends in known diabetes
In . Tab. 5,  the lifetime prevalence of 
known diabetes from the earlier exam-
ination survey is compared with that 
from DEGS1. The lifetime prevalence ob-
served on the basis of the GNHIES98 data 
(weighted to 1997 population structure) 
was 5.2% overall (women: 5.7%; men: 
4.7%). This resulted in a significant ab-
solute increase in prevalence over time 
of 2.0% (women: 1.7%; men: 2.3%) and 
a relative increase of 38% (women: 30%; 
men: 49%). A significant increase also ex-
ists after taking the demographic ageing 
of the population into account (weighted 
to 2010 population structure). This is 1.4% 
absolute (women: 1.3%; men: 1.6%) and 
24% relative (women: 21%; men: 30%). 
Consequently, an absolute increase of 
0.6% (women: 0.4%; men: 0.7%) and rel-
ative increase of 14% (women: 9%; men: 
19%) can be attributed to demographic 
ageing.
Extrapolations of the GNHIES98 da-
ta show that approximately 10 years ago 
a total of 3.3 million of 18- to 79-year-
olds living in Germany had at some point 
been diagnosed with diabetes. By con-
trast, according to the estimations based 
on DEGS1 data, diabetes has been diag-
nosed at some point in a total of 4.6 mil-
lion people in this age group.
Discussion
According to the current DEGS1 data, 
7.2% or 4.6 million of the 18- to 79-year-
old population of Germany have at some 
point been diagnosed with diabetes. The 
lifetime prevalence of known diabetes in-
creases substantially with age and is high-
er amongst those of low socioeconomic 
status than high socioeconomic status. 
Prevalence is higher in persons insured in 
statutory health insurance schemes—es-
pecially those insured with AOK—than it 
is amongst those with private medical in-
surance. In addition, there are indications 
of regional differences, especially with re-
gard to a tendency toward a higher preva-
lence in the new federal states compared 
to the old ones. In comparison to GN-
HIES98, the prevalence of known diabe-
tes has increased by 38%. An increase of 
14% is to be attributed to the demograph-
ic ageing of the population.
Prevalence of known diabetes
The most recent health surveys conduct-
ed at population level as telephone in-
terviews, GEDA 2009 and GEDA 2010, 
yielded a pooled lifetime prevalence of 
8.7% or a figure of 5.9 million adults aged 
18 years and above having been diag-
nosed with diabetes at some point. Lim-
iting the GEDA data to the age range 
of 18–79 years results in a prevalence of 
8.2%, which exceeds the observed preva-
lence of 7.2% in DEGS1. Conversely, a di-
abetes prevalence in the age group over 
80 years observed in GEDA and oth-
er studies, similar in size to that in the 
70–79-year age range [20, 21, 22, 23, 24, 
25, 26], results in a figure of only 5.5 mil-
lion adults over 18 years with known dia-
betes when the data are transposed onto 
DEGS1. This difference in size of the esti-
mates between DEGS1 and GEDA is pre-
sumably a result of the difference in sam-
ple composition due to a different sam-
Tab. 3 Lifetime prevalence (percent, 95% confidence interval) of known diabetes according 





  Overall North Central South  
Gender          
Female 7.1 (6.0–8.4) 7.1 (4.6–10.9) 7.7 (6.3–9.4) 6.3 (4.6–8.6) 8.7 (6.7–11.3)
Male 6.9 (5.7–8.2) 6.3 (4.3–9.3) 7.5 (5.6–10.0) 6.3 (4.7–8.4) 7.5 (5.9–9.4)
Overall 7.0 (6.2–7.9) 6.7 (5.2–8.7) 7.6 (6.3–9.2) 6.3 (5.1–7.8) 8.1 (6.9–9.5)
Old federal states: North: Schleswig-Holstein, Hamburg, Lower Saxony, Bremen; Central: North Rhine-Westpha-
lia, Hessen, Rhineland Palatinate, Saarland; South: Bavaria, Baden-Wuerttemberg
Tab. 2 Lifetime prevalence (percent, 95% confidence interval) of known diabetes according 
to gender and socioeconomic status. Nunweighted=7,012
Socioeconomic status Low Middle High
Gender      
Female 11.6 (8.6–15.5) 7.4 (6.3–8.7) 3.0 (2.0–4.5)
Male 10.1 (7.5–13.5) 6.1 (5.1–7.4) 6.2 (4.6–8.3)
Overall 10.9 (8.8–13.5) 6.8 (6.0–7.7) 4.8 (3.7–6.0)
Socioeconomic status: index that includes information on school and vocational education, professional 
position and net household income (weighted by household needs)
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pling procedure (local population regis-
try sample vs. private households avail-
able via landline) and a different survey 
method (personal physician-adminis-
tered interview vs. telephone interview). 
For a direct comparison, the DEGS1 data 
were consequently compared exclusively 
with the GNHIES98 data, which are the 
most recent data gathered by a compara-
ble method.
The nationwide surveys conduct-
ed on a postal-written basis by the Ber-
telsmann Healthcare Monitor indicate a 
prevalence for known diabetes of 8.0% in 
the 18–79-year age range for 2008 [27]. 
This prevalence is therefore between the 
lifetime prevalence established in DEGS1 
(2008–11) at 7.2% and that of GEDA 
(2008–10) at 8.2%. On the other hand, 
the AOK Hesse/KV Hesse sample points 
to a prevalence of 9.8% for insured per-
sons of all age groups for 2009 [5] (18- to 
79-year-olds, excluding in-patient care 
cases: 10.2%), which is higher than the 
prevalence found in GEDA (2008–2010) 
for adults aged 18 years and above at 8.7% 
(18- to 79-year-olds: 8.2%). This expected 
difference is, however, in agreement with 
the present observations from DEGS1 and 
other current analyses [27, 28], according 
to which persons insured with AOK have 
the highest prevalence of diabetes when 
compared to those otherwise insured. In 
addition to deviations in age structure, 
which can largely be taken into account 
in age-standardised analyses, differences 
in educational status and in the existence 
of co-morbidities play a role here [29].
The results of further studies regard-
ing known diabetes in Germany that 
are shown in . Tab. 6 are not compara-
ble with the current results because the 
study periods were before the DEGS1 pe-
riod. Regarding the relatively high prev-
alence of known diabetes in the patient 
samples of general practices, it should be 
noted that more people with diagnosed 
diabetes are to be expected amongst the 
practice patients than in the general pop-
ulation. Overall and similarly to DEGS1, 
the studies summarised in . Tab. 6—in 
addition to the aforementioned differ-
ences depending on the type of health in-
surance—point toward a clear increase in 
prevalence with increasing age, especially 
from the age of 50 years onwards [8, 20, 
21, 22, 23, 24, 25, 26, 28, 30, 31, 32, 33, 34, 
35, 36, 37], as well as social differences [8, 
27] and regional trends [8, 10, 27, 32] in 
the prevalence of diabetes.
Data regarding the prevalence of 
type-1 diabetes are only to be found in a 
few patient samples [25, 37, 38]. The pro-
portion of type-1 diabetes of the respec-
tive overall prevalence of known diabe-
tes in these samples is between approxi-
mately 3% and 6% and is therefore higher 
than the DEGS1 figure of about 1%. Given 
this difference in size, the rather conser-
vative estimation of type-1 diabetes prev-
alence in DEGS1 by using the available in-
formation, along with variations in study 
design, has to be taken into account. Da-
ta on the prevalence of gestational diabe-
tes were not reported in any of the stud-
ies summarised in . Tab. 6.
Temporal trends in known diabetes
The first time series for Germany regard-
ing the prevalence of known diabetes is 
based on data from the diabetes register of 
the former GDR, which existed between 
1960 and 1989. For this period, a contin-
ual increase in prevalence from 0.6% to 
4.1% was observed, which was mostly at-
tributable to the increase in prevalence in 
the over 50-year age group [20, 39]. Data 
on the prevalence trend in the old federal 
states do not exist for this period.
For the subsequent period until about 
2000, based on the data from population-
based studies, there is no evidence of a 
further increase in prevalence. No trend 
in diabetes prevalence was observed ei-
ther in the surveys conducted as part of 
the German Cardiovascular Prevention 
Study in the old federal states for 25- to 
69-year-olds between 1984–1986 and 
1990–1991 [31] or in the KORA/MON-
ICA surveys in the Augsburg region for 
25- to 64-year-olds between 1984–1985 
and 1999–2001 or for 25- to 74-year-olds 
between 1989–1990 and 1999–2001 [35]. 
Similarly, the comparison of data from 
the nationwide  examination surveys 





















Gender              
Female 7.8 (6.7–9.0) 8.6 (6.6–11.2) 7.3 (5.7–9.2) 6.8 (4.7–9.9) 8.9 (5.7–13.6) 1.2 (0.3–3.9) 4.7 (2.4–9.3)
Male 7.2 (6.1–8.5) 9.5 (7.4–12.0) 6.7 (5.0–8.8) 5.0 (3.2–7.7) 7.0 (4.5–10.5) 5.0 (2.8–8.7) 4.7 (2.6–8.4)
Overall 7.5 (6.7–8.4) 9.0 (7.5–10.8) 7.0 (5.9–8.3) 5.9 (4.4–7.8) 7.9 (5.7–10.8) 3.8 (2.2–6.5) 4.7 (3.1–7.0)
Tab. 5 Lifetime prevalence (percent, 95% confidence interval) of known diabetes according 
to gender compared over time. N(DEGS1)unweighted=7,080, N(GNHIES98)unweighted=7,099
Survey GNHIES98a GNHIES98b DEGS1b
Gender      
Female 5.7 (4.8–6.7) 6.1 (5.1–7.2) 7.4 (6.5–8.5)
Male 4.7 (4.1–5.4) 5.4 (4.7–6.3) 7.0 (6.0–8.1)
Overall 5.2 (4.6–5.9) 5.8 (5.1–6.5) 7.2 (6.5–8.0)
aWeighted to population distribution as of 31 December 1997
bWeighted to population distribution as of 31 December 2010
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18–79 years, N=7.080 
(. Tab. 4, . Tab. 5)





diagnosed diabetes or 
anti-diabetic medication
Overall: 7.2% (women: 7.4%, men: 
7.0%)
Type-1: 0.1%, Gestational diabetes/
women: 1.2%
AOK: 9.0%; EKK: 7.0%; BKK: 5.9%; other 
statutory insurance: 7.9%; PKV: 3.8%; 
other provision: 4.7%
GNHIES98;




Overall: 5.2% (women: 5.7%, men: 
4.7%)
East/West Health Survey 91, representative survey of residential 
population in the new and old federal states;
25–69 years, N≈7.450 [30]
1990–1992
(1991)
Self-report on diabetes 
diagnosis
Women: 4.7%, men: 5.0%
German Cardiovascular Prevention Study, representative survey 
of residential population in the old federal states;





1990/1991: women: 4.1%, men: 4.6%
1987/1988: women: 3.8%, men: 5.3%
1984–1986: women: 4.6%, men: 4.5%
Nationwide telephone survey
GEDA 2010;
18+ years, N=22.050 [10]
Representative survey of German 
speaking resident population in 






Overall: 8.6% (women: 8.8%; men: 
8.5%)
GEDA 2009;
18+ years, N=21.262 [8, 9]
2008/2009
(31/12/2007)
Overall: 8.8% (women: 9.3%, men: 
8.2%)
GSTel03;
18+ years, N=8.318 [8, 9]
2002/2003
(31/12/2001)
Overall: 6.1% (women: 6.8%, men: 
5.4%)
GSTel03, GSTel04 (pooled);




AOK: 10.1%; EKK: 5.6%; BKK: 4.7%; 
other statutory insurance: 6.6%; PKV: 
4.8%
Nationwide postal survey
Bertelsmann Healthcare Monitor, representative survey of Ger-
man-speaking resident population in Germany;
18–79 years, N=15.089 (N≈1.500 per survey) [27]
2004–2008 Self-report on diabetes 
diagnosis (≥1 physician 
visit per quarter or regu-
lar use of medication
Overall 6.9% (women: 5.8%, men: 
8.0%)
2008: 8.0%, 2007: 7.2%, 2006: 6.5%, 
2005: 6.4%, 2004: 6.2%
AOK: 11.4%; Barmer: 8.5%; DAK: 6.5%; 
BKK: 5.9%; TKK: 5.8%; PKV: 4.6%; IKK: 
3.9%; other provision: 5.2%
Registry data
Diabetes register of the former GDR;






Diabetes register of the former GDR;
All age groups, population of East Berlin [47]
1960–1989 1988: 3.8% (women: 4.5%, men: 3.0%)
1970: 2.5% 
Regional study
Rural Health Study, sample from randomly selected north-east 
German rural communities;





Self-report on diabetes 
diagnosis
2004/2008: women: 12.4%, men: 
12.8%
1994: women: 10.9%, men: 6.8%
1973: women: 3.5%, men: 3.1%
DIAB-CORE Consortium including GNHIES98 (1997–99) and 
the regional studies CARLA (2002–06), DO-GS (2003/04), HNR 
(2000–03), KORA S4 (1999–2001), SHIP (1997–2001);
45–74 years, N=15.071 [32]
1997–2006
(31/12/2007)
Self-report on diabetes 
diagnosis or anti-diabetic 
medication and age at 
diagnosis >30 Years
Type-2: 8.6%
GNHIES98: 8.2%; CARLA: 12.0%; DO-
GS: 9.3%; HNR: 7.2%; KORA: 5.8%; SHIP: 
10.9%
KORA F4 (follow-up), cohort study in the Augsburg region;




diagnosed diabetes or 
anti-diabetic medication 
(verified)
Overall: 2.2% (women: 2.3%, men: 
2.2%)
KORA S4, survey in the Augsburg region;
55–74 years, N=1.353 [34]
1999–2001
(31/12/2000)








MONICA/KORA, surveys in the Augsburg region;
25–64 years (19984/85), 25–74 years (subsequent surveys), 







diagnosed diabetes or 
anti-diabetic medication
25–64 years:
1999–2001: women: 2.7%, men: 2.5%
1994/1995: women: 2.5%, men: 3.0%
1989/1990: women: 2.3%, men: 3.6%
1984/85: women: 2.0%, men: 2.7%
25–74 years:
1999–2001: women: 3.5%, men: 3.7%
1994/1995: women: 3.7%, men: 4.1%
1989/90: women: 3.6%, men: 4.6%
EPIC-Potsdam, baseline examination of a cohort study in the 
Potsdam region;




diagnosed diabetes or 
diabetic therapy
Women: 2.6%, men: 3.7%
Sample from randomly selected towns and rural areas in 5 federal 
states;
18–70 years, N=2.150 [36]
1993–1996 Self-report on diabetes 
diagnosis or diabetes 
therapy
Overall: 6.3% 
Study on early detection of diabetes in Munich;
All age groups, N≈790.000 [49]




AOK Hesse/KV Hesse Statutory Health Insurance Sample;




diabetes (in ≥3 of 4 
quarters) or prescription 
of anti-diabetic medica-
tion (≥2 per annum or 1 
per annum plus diabetes 
diagnosis or plus glucose- 
or HbA1c-measurement 
in the same quarter)
2009: 9.8%
2000: 7.5%
AOK Hesse/KV Hesse Statutory Health Insurance Sample;
All age groups, N≈300.000 per annum [50]
2000–2007




AOK Hesse/KV Hesse Statutory Health Insurance Sample;
All age groups, N≈300.000 per annum [21, 22]
1998–2004
(31/12 of the 
previous year)
2004: 7.9% (women: 8.1%, men 7.6%)
2001: 6.9% (women: 7.4%, men: 6.5%)
1998: 5.9%
Sample of insured persons from six statutory health insurance 
funds;
All age groups, N=14.7 million [23]
1999 Diabetes diagnosis or pre-
scription of anti-diabetic 
medication
Overall: 6.5%
Sample of insured persons from the AOK-Dortmund;




diabetes (in ≥2 of 4 quar-
ters) or prescription of 
anti-diabetic medication 
(≥4 per annum) or blood 
glucose measurement (in 
≥3 of 4 quarters)
Overall: 4.8% (women: 5.5%, men: 
4.1%)
Patient data
GEMCAS, national sample of patients from general practices;






Type-1: 0.7%, Type-2: 11.1% 
DETECT study, national sample of patients from general practices;
18+ years, N=55.518 (N=3.188 practices) [37]
2003 Physician data on dia-
betes diagnosis on day 
of study or anti-diabetic 
medication
Overall: 15.2%
Type-1: 0.5%, Type-2: 14.7%
ESTHER, sample of patients from health check-ups in general 
practices in the Saarland;
50–74 years, N=9.953 [51]
2000–2002 Physician-diagnosed 
diabetes or anti-diabetic 
medication
Overall: 13.8%
HYDRA-study, national sample of patients from general practices/
internists in private practice;
16+ years, N=43.549 (N=1.912 practices) [26]
2001 Physician data on diabe-
tes diagnosis on day of 
study
Overall:15.6% (women: 13.7%, men: 
18.5%)
SESAM 2, sample of patients from general practices in Saxony;






Type-1: 0.3%, Type-2: 6.2%, Other 
types: 1.8%, types not further speci-
fied: 1.0%
aDeviation in the data in Thefeld et al. [30] from . Tab. 5 is a result of the non-consideration of anti-diabetic medication in the definition of diabetes
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shows no increase in prevalence for the 
25- to 69-year-old population between 
1990–1992 and 1997–1999 [30]—neither 
for the new nor for the old federal states 
[40]. Furthermore, no trend can be seen 
in an extension of this comparison over 
time that includes the data from the tele-
phone health surveys of 2002–2005 [40].
A comparison of the DEGS1 data with 
those from GNHIES98 as described in 
the results section, indicates, in agree-
ment with other current investigations, 
an increase in the prevalence of known 
diabetes within the last decade. The in-
crease for the 18- to 79-year-old popula-
tion amounts to 38% on the basis of the 
examination surveys performed between 
1997–1999 and 2008–2011 and 29% on 
the basis of the Bertelsmann Healthcare 
Monitor survey between 2004 and 2008 
[27]. For adults aged 18 years and above, 
an increase of 43% can be observed based 
on the telephone surveys between 2002–
2003 and 2008–2010 and 49% based on 
the AOK Hesse/KV Hesse sample of in-
sured persons between 2000 and 2009 
[5]. A greater increase is evident in men 
than in women: In the examination sur-
veys this amounts to 49% versus 30%, in 
the telephone surveys 54% versus 34% 
and in the sample of insured persons 
57% versus 40%. In addition, data analy-
sis of the examination surveys shows—in 
accordance with the results of the AOK 
Hesse/KV Hesse sample of insured per-
sons [5]—that approximately one third of 
the increase observed can be attributed to 
demographic ageing within the observa-
tion period.
Projections of the prevalence of known 
type-2 diabetes for the year 2030—which 
are calculated on the basis of the diabetes 
prevalence data of population-based re-
gional studies and of GNHIES98 (DIAB-
CORE Consortium), diabetes incidence 
and mortality data from the Augsburg re-
gion (KORA S4/F4) and the Federal Sta-
tistical Office population forecast—show 
an increase of approximately 1.5 million 
persons for the 55- to 74-year-olds alone 
(+64%) compared to today [41]. A more 
pronounced increase of almost 1 million 
people was projected for men (+79%) 
than for women at over 0.5 million peo-
ple (+47%).
Factors relevant to the 
interpretation of the prevalence 
of known diabetes
The magnitude of known diabetes is de-
pendent on the ratio of diagnosed-to-
undiagnosed cases. Isolated analyses to 
estimate this ratio lead to different re-
sults owing to differing study popula-
tions and study periods and especially 
owing to varying diagnosis criteria. Re-
sults of the oral glucose tolerance test as 
part of the KORA Study in the Augsburg 
region indicate a prevalence of undiag-
nosed diabetes (defined as fasting glucose 
≥7.0 mmol/l or glucose following the oral 
glucose tolerance test ≥11.1 mmol/l) that 
is just as high as that of diagnosed dia-
betes [33, 34]. On the contrary, prelimi-
nary evaluations from DEGS1, in which 
no oral glucose tolerance test was con-
ducted but in which laboratory values ex-
ist for fasting glucose (48% of the sample) 
or random glucose and for HbA1c, indi-
cate a prevalence of undiagnosed diabe-
tes (defined as HbA1c ≥6.5% or fasting-
glucose ≥7.0 mmol/l or random-glucose 
≥11.1 mmol/l) [42] that is more than three 
times lower than that of known diabetes. 
In earlier studies in which no oral glucose 
tolerance test was conducted, the preva-
lence of undiagnosed diabetes based on 
various criteria was also substantially 
lower than the prevalence of diagnosed 
diabetes [25, 30, 36].
The ratio of diagnosed-to-undiag-
nosed diabetes can shift over the course 
of time. Thus, improved screening meth-
ods, increased attention by doctors (for 
example through the introduction of dis-
ease management programmes) and im-
proved knowledge about symptoms on 
the part of the patients all lead to the ear-
lier discovery of persons with diabetes. 
Consequently, the proportion of diag-
nosed cases increases whilst the propor-
tion of undiagnosed cases falls. Thus, da-
ta on the trend in undiagnosed diabetes, 
which are gathered over time using com-
parable methods, are essential for the in-
terpretation of the trends observed in 
known diabetes. However, there are no 
such data yet for Germany [11]. Planned 
comparative analyses of DEGS1 and GN-
HIES98 will be able to provide an indica-
tion of this for the first time.
The prevalence of known diabetes—
and also that of undiagnosed diabetes—is 
furthermore dependent on the incidence 
and mortality rates. The incidence rate is 
closely linked with behaviour (such as di-
et, physical activity and associated body 
weight) and living conditions (such as 
personal or regional economic factors, air 
pollution), which play a role in the devel-
opment of diabetes [2]. This means that 
the observed increase in obesity [43], the 
main risk factor for diabetes, will proba-
bly as a consequence lead to an increase 
in the incidence of diabetes. In addition 
to general life expectancy, the mortality 
rate of persons with diabetes is associated 
with treatment intensity or rather treat-
ment success. Thus, given a higher gen-
eral life expectancy and improved treat-
ment possibilities, a higher prevalence 
would also be expected. So far, popula-
tion-based data on incidence and mor-
tality—other than from the diabetes reg-
ister of the former GDR—are only avail-
able from the Augsburg region [44, 45].
The monitoring data of the RKI will 
also be able to contribute towards esti-
mating nationwide diabetic incidence 
and mortality and temporal trends there-
in.
Strengths and limitations
The strengths of this study lie in the pop-
ulation representativeness of the preva-
lence estimates for the German resident 
population aged 18–79 years, and in the 
comparability of the prevalence figures 
at two points in time more than 10 years 
apart due to identical sampling and def-
inition of known diabetes. Estimates of 
prevalence and extrapolations for the 
population are made possible by weight-
ing the results with complex weight-
ing factors, which take into account the 
complex design of the study, the non-re-
sponse, and re-participation of the GN-
HIES98 participants [15, 16]. The lim-
itations of this study are that the popu-
lation aged 80 years and above and cer-
tain groups of people (especially care-
home residents and severely ill persons) 
could not be included representatively in 
the examination survey. In addition, no 
comprehensive assessment of disease de-
velopment is possible since the estima-
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tions here are limited to already diag-
nosed diabetes. Furthermore, the defini-
tion of known diabetes is mainly based on 
self-reports by participants, which could, 
however, be evaluated as a relatively valid 
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